Bupropion for the treatment of seasonal affective disorder

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 9, 2013, Pages 1229-1240

  Niemegeers, Peter ^a   Dumont, Glenn Jh ^a   Patteet, Lisbeth ^b   Neels, Hugo ^b,d   Sabbe, Bernard Gc ^a,c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Psychiatric Centre Sint Norbertushuis   (Belgium)

^d Laboratory for TDM and Toxicology   (Belgium)

Author keywords

Bupropion; Depression; Pharmacokinetics; Seasonal affective disorder

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2B6; CYTOCHROME P450 2D6; DOPAMINE; NICOTINIC RECEPTOR; NORADRENALIN;

AGITATION; ANXIETY; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DSM-IV; HUMAN; INSOMNIA; KIDNEY FUNCTION; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; PHARMACODYNAMICS; PHARMACOLOGICAL BLOCKING; SEASONAL AFFECTIVE DISORDER; SIDE EFFECT; TREMOR;

ANTIDEPRESSIVE AGENTS; BUPROPION; DELAYED-ACTION PREPARATIONS; DRUG EVALUATION, PRECLINICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEASONAL AFFECTIVE DISORDER;

EID: 84882292537     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.804062     Document Type: Article

References (97)

1. Partonen T, Lonnqvist J. Seasonal affective disorder. Lancet 1998;352(9137):1369-74
2. Wehr TA, Giesen HA, Schulz PM, et al. Contrasts between symptoms of summer depression and winter depression. J Affect Disord 1991;23(4):173-83
3. American Psychiatric Association. Diagnostic and statistical manual of mental health disorders. Revised 4th edition. American Psychiatric Association, Washington DC; 1994
4. Kurlansik SL, Ibay AD. Seasonal affective disorder. Am Fam Physician 2012;86(11):1037-41
5. Levitan RD. The chronobiology and neurobiology of winter seasonal affective disorder. Dialogues Clin Neurosci 2007;9(3):315-24
6. Clinical Study Registry. GlaxoSmithKline. GlaxoSmithKline, Middlesex, United Kingdom; 2013. Available from: http://www.gsk-clinicalstudyregister.com/ [Last accessed 3 February 2013]
7. Ravindran AV, Lam RW, Filteau MJ, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. J Affect Disord 2009;117(Suppl 1):S54-64
8. Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 2005;162(4):656-62
9. Partonen T, Lonnqvist J. Prevention of winter seasonal affective disorder by bright-light treatment. Psychol Med 1996;26(5):1075-80
10. Terman M, Terman JS. Treatment of seasonal affective disorder with a high-output negative ionizer. J Altern Complement Med 1995;1(1):87-92
11. Terman M, Terman JS. Controlled trial of naturalistic dawn simulation and negative air ionization for seasonal affective disorder. Am J Psychiatry 2006;163(12):2126-33
12. Flory R, Ametepe J, Bowers B. A randomized, placebo-controlled trial of bright light and high-density negative air ions for treatment of Seasonal Affective Disorder. Psychiatry Res 2010;177(1-2):101-8
13. Avery DH, Eder DN, Bolte MA, et al. Dawn simulation and bright light in the treatment of SAD: a controlled study. Biol Psychiatry 2001;50(3):205-16
14. Rohan KJ, Roecklein KA, Tierney Lindsey K, et al. A randomized controlled trial of cognitive-behavioral therapy, light therapy, and their combination for seasonal affective disorder. J Consult Clin Psychol 2007;75(3):489-500
15. Moscovitch A, Blashko CA, Eagles JM, et al. A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology (Berl) 2004;171(4):390-7
16. Lam RW, Gorman CP, Michalon M, et al. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 1995;152(12):1765-70
17. Lam RW, Levitt AJ, Levitan RD, et al. The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. Am J Psychiatry 2006;163(5):805-12
18. Ruhrmann S, Kasper S, Hawellek B, et al. Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychol Med 1998;28(4):923-33
19. Partonen T, Lonnqvist J. Moclobemide and fluoxetine in treatment of seasonal affective disorder. J Affect Disord 1996;41(2):93-9
20. Lingjaerde O, Reichborn-Kjennerud T, Haggag A, et al. Treatment of winter depression in Norway. II. A comparison of the selective monoamine oxidase A inhibitor moclobemide and placebo. Acta Psychiatr Scand 1993;88(5):372-80
21. Pjrek E, Winkler D, Stastny J, et al. Escitalopram in seasonal affective disorder: results of an open trial. Pharmacopsychiatry 2007;40(1):20-4
22. Pjrek E, Willeit M, Praschak-Rieder N, et al. Treatment of seasonal affective disorder with duloxetine: an open-label study. Pharmacopsychiatry 2008;41(3):100-5
23. Pjrek E, Winkler D, Konstantinidis A, et al. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl) 2007;190(4):575-9
24. Hilger E, Willeit M, Praschak-Rieder N, et al. Reboxetine in seasonal affective disorder: an open trial. Eur Neuropsychopharmacol 2001;11(1):1-5
25. Shen J, Kennedy SH, Levitan RD, et al. The effects of nefazodone on women with seasonal affective disorder: clinical and polysomnographic analyses. J Psychiatry Neurosci 2005;30(1):11-16
26. Dilsaver SC, Jaeckle RS. Winter depression responds to an open trial of tranylcypromine. J Clin Psychiatry 1990;51(8):326-9
27. Dilsaver SC, Qamar AB, Del Medico VJ. The efficacy of bupropion in winter depression: results of an open trial. J Clin Psychiatry 1992;53(7):252-5
28. Hesselmann B, Habeler A, Praschak-Rieder N, et al. Mirtazapine in seasonal affective disorder (SAD): a preliminary report. Hum Psychopharmacol 1999;14(1):59-62
29. Thorell LH, Kjellman B, Arned M, et al. Light treatment of seasonal affective disorder in combination with citalopram or placebo with 1-year follow-up. Int Clin Psychopharmacol 1999;14(Suppl 2):S7-11
30. Kasper S. Treatment of seasonal affective disorder (SAD) with hypericum extract. Pharmacopsychiatry 1997;30(Suppl 2):89-93
31. Martinez B, Kasper S, Ruhrmann S, Moller HJ. Hypericum in the treatment of seasonal affective disorders. J Geriatr Psychiatry Neurol 1994;7(Suppl 1):S29-33
32. Wheatley D. Hypericum in seasonal affective disorder (SAD). Curr Med Res Opin 1999;15(1):33-7
33. McGrath RE, Buckwald B, Resnick EV. The effect of L-tryptophan on seasonal affective disorder. J Clin Psychiatry 1990;51(4):162-3
34. Modell JG, Rosenthal NE, Harriett AE, et al. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiatry 2005;58(8):658-67
35. Martiny K, Lunde M, Simonsen C, et al. Relapse prevention by citalopram in SAD patients responding to 1 week of light therapy. A placebo-controlled study. Acta Psychiatr Scand 2004;109(3):230-4
36. WELLBUTRIN-(bupropion hydrochloride) Tablets. GlaxoSmithKline. GlaxoSmithKline, Research Triangle Park, NC; 2011. Available from: http://us.gsk.com/products/assets/us-wellbutrin-tablets.pdf [Last accessed 26 December 2012]
37. APLENZIN-(bupropion hydrobromide) Extended-Release Tablets. sanofi-aventis U.S. LLC. sanofi-aventis U.S. LLC, Bridgewater, NJ; 2012. Available from: http://products. sanofi.us/aplenzin/aplenzin.pdf [Last accessed 26 December 2012]
38. WELLBUTRIN SR-(bupropion hydrochloride) Sustained-Release Tablets. GlaxoSmithKline. GlaxoSmithKline, Research Triangle Park, NC; 2011. Available from: http://us.gsk.com/products/assets/us-wellbutrinSR.pdf [Last accessed 26 December 2012]
39. ZYBAN SR-(bupropion hydrochloride) Sustained-Release Tablets. GlaxoSmithKline. GlaxoSmithKline, Research Triangle Park, NC; 2012. Available from: http://us.gsk.com/products/assets/us-zyban.pdf [Last accessed 26 December 2012]
40. WELLBUTRIN XL-(bupropion hydrochloride) tablet, extended release. BTA Pharmaceuticals. BTA Pharmaceuticals, Inc., Bridgewater, NJ; 2011. Available from: http://www.wellbutrinxl.com/Portals/24/Documents/WellbutrinXL-Full- Prescribing-Information.pdf [Last accessed 26 December 2012]
41. Bowers GN Jr, Onoroski M. Hyperchloremia and the incidence of bromism in 1990. Clin Chem 1990;36(8 Pt 1):1399-403
42. van Gelderen CE, Savelkoul TJ, Blom JL, et al. The no-effect level of sodium bromide in healthy volunteers. Hum Exp Toxicol 1993;12(1):9-14
43. EMEA/MRL/182/97-FINAL: bromide, Sodium salt, Summary Report. Committee for veterinary medicinal products. The European Agency for the Evaluation of Medicinal Products. March 1997. Available from: http://www.ema.europa.eu/docs/ en-GB/document-library/Maximum-Residue-Limits-Report/2009/11/WC500011113.pdf [Last accessed 12 March 2013]
44. Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004;6(4):159-66
45. Learned-Coughlin SM, Bergstrom M, Savitcheva I, et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 2003;54(8):800-5
46. Arias HR. Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? Int J Biochem Cell Biol 2009;41(11):2098-108
47. Miller L, Griffith J. A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers. Psychopharmacology (Berl) 1983;80(3):199-205
48. Griffith JD, Carranza J, Griffith C, Miller LL. Bupropion: clinical assay for amphetamine-like abuse potential. J Clin Psychiatry 1983;44(5 Pt 2):206-8
49. McCormick J. Recreational bupropion abuse in a teenager. Br J Clin Pharmacol 2002;53(2):214
50. Khurshid KA, Decker DH. Bupropion insufflation in a teenager. J Child Adolesc Psychopharmacol 2004;14(1):157-8
51. Hill S, Sikand H, Lee J. A case report of seizure induced by bupropion nasal insufflation. Prim Care Companion J Clin Psychiatry 2007;9(1):67-9
52. Kim D, Steinhart B. Seizures induced by recreational abuse of bupropion tablets via nasal insufflation. CJEM 2010;12(2):158-61
53. Findlay JW, Van Wyck Fleet J, Smith PG, et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 1981;21(2):127-35
54. Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 2005;27(11):1685-95
55. GlaxoSmithKline. Study Single-Dose Bioequivalence of WELLBUTRIN- Sustained-Release Tablets Versus WELLBUTRIN Immediate-Release Tablets in Healthy Male Volunteers. A Pilot Study. GlaxoSmithKline, Research Triangle Park, NC; 1991
56. GlaxoSmithKline. Study teady-state bioequivalence evaluation of bupropion sustained-release and bupropion immediate-release tablets in healthy male volunteers. GlaxoSmithKline, Research Triangle Park, NC; 1992
57. GlaxoSmithKline. Study AK1BIOVAIL2543. A two-way, crossover, steady state, multiple-dose, open-label, fasting, comparative bioavailability study of bupropion HCI 300 mg extended release tablets (1 X 300 mg q.d.) versus WELLBUTRIN 100 mg tablets (t.i.d.) in normal healthy non-smoking male and female subjects. GlaxoSmithKline, Research Triangle Park, NC; 2001
58. GlaxoSmithKline. Study AK1BIOVAIL2572. A two-way, steady state, crossover, open-label, multiple-dose, fasting, comparative bioavailability study of bupropion HCI 300 mg extended-release tablets versus ZYBAN 150 mg tablets in normal healthy non-smoking male and female subjects. GlaxoSmithKline, Research Triangle Park, NC; 2002
59. Hsyu PH, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997;37(8):737-43
60. Kokras N, Dalla C, Papadopoulou-Daifoti Z. Sex differences in pharmacokinetics of antidepressants. Expert Opin Drug Metabol Toxicol 2011;7(2):213-26
61. Schroeder DH. Metabolism and kinetics of bupropion. J Clin Psychiatry 1983;44(5 Pt 2):79-81
62. Coles R, Kharasch ED. Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes. Pharm Res 2008;25(6):1405-11
63. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000;28(10):1176-83
64. Turpeinen M, Tolonen A, Uusitalo J, et al. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005;77(6):553-9
65. Hogeland GW, Swindells S, McNabb JC, et al. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 2007;81(1):69-75
66. Hesse LM, Greenblatt DJ, von Moltke LL, Court MH. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J Clin Pharmacol 2006;46(5):567-76
67. Park J, Vousden M, Brittain C, et al. Dose-related reduction in bupropion plasma concentrations by ritonavir. J Clin Pharmacol 2010;50(10):1180-7
68. Ketter TA, Jenkins JB, Schroeder DH, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995;15(5):327-33
69. Reese MJ, Wurm RM, Muir KT, et al. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 2008;36(7):1198-201
70. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009;70(12):1688-97
71. Weintraub D. Nortriptyline toxicity secondary to interaction with bupropion sustained-release. Depress Anxiety 2001;13(1):50-2
72. Shad MU, Preskorn SH. A possible bupropion and imipramine interaction. J Clin Psychopharmacol 1997;17(2):118-19
73. DeVane CL, Laizure SC, Stewart JT, et al. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 1990;10(5):328-32
74. GlaxoSmithKline. Study WELL AK1B1001. The pharmacokinetics and tolerability of Wellbutrin SR after oral administration of a single 150 mg dose in patients with liver cirrhosis and healthy volunteers. GlaxoSmithKline, Research Triangle Park, NC; 1997
75. Earhart AD, Patrikeeva S, Wang X, et al. Transplacental transfer and metabolism of bupropion. J Matern Fetal Neonatal Med 2010;23(5):409-16
76. Alwan S, Reefhuis J, Botto LD, et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010;203(1):52 e1 6
77. Thyagarajan V, Robin Clifford C, Wurst KE, et al. Bupropion therapy in pregnancy and the occurrence of cardiovascular malformations in infants. Pharmacoepidemiol Drug Saf 2012;21(11):1240-2
78. Worrall SP, Almond MK, Dhillon S. Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. A single dose study. Nephron Clin Pract 2004;97(3):c83-9
79. Turpeinen M, Koivuviita N, Tolonen A, et al. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br J Clin Pharmacol 2007;64(2):165-73
80. GlaxoSmithKline. Study 40UKA. The disposition of bupropion and its basic metabolites in young and elderly healthy volunteers. GlaxoSmithKline, Research Triangle Park, NC; 1984
81. Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokinetics of single-and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995;35(9):876-84
82. GlaxoSmithKline. Study WELL AK130930. A 7-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of 150-300 mg/day of Extended-Release Bupropion Hydrochloride (WELLBUTRIN XL) and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder Followed by an 8-Week Observational Follow-up Phase. GlaxoSmithKline, Research Triangle Park, NC; 2002
83. GlaxoSmithKline. Study WELL AK130936. A 7-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of 150-300 mg/day of Extended-Release Bupropion Hydrochloride (WELLBUTRIN XL) and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder Followed by an 8-Week Observational Follow-up Phase. GlaxoSmithKline, Research Triangle Park, NC; 2002
84. GlaxoSmithKline. Study WELL 100006. A 7-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of 150-300 mg/day of Extended-Release Bupropion Hydrochloride (WELLBUTRIN XL) and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder Followed by an 8-Week Observational Follow-up Phase. GlaxoSmithKline, Research Triangle Park, NC; 2003
85. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29(3):259-66
86. Kumar S, Kodela S, Detweiler JG, et al. Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature. Gen Hosp Psychiatry 2011;33(6):612-17
87. Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991;52(11):450-6
88. Dunner DL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998;59(7):366-73
89. Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract 2005;59(12):1435-40
90. Wightman DS, Foster VJ, Krishen A, et al. Meta-analysis of suicidality in placebo-controlled clinical trials of adults taking bupropion. Prim Care Companion J Clin Psychiatry 2010;12(5):e1-e8
91. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009;339:b2880
92. Schneeweiss S, Patrick AR, Solomon DH, et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry 2010;67(5):497-506
93. Thase ME, Haight BR, Johnson MC, et al. A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol 2008;28(3):302-7
94. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003;24(10):946-55
95. Rigotti NA, Thorndike AN, Regan S, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med 2006;119(12):1080-7
96. Drug Product Database. Health Canada. Health Canada, Ontario, Canada; 2013. Available from: http://www.hc-sc. gc.ca/dhp-mps/prodpharma/databasdon/ index-eng.php [Last accessed 12 March 2013]
97. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287(14):1840-7